Difference between revisions of "How I Treat"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 231: Line 231:
 
*'''2020:''' Martin. [https://doi.org/10.1182/blood.2019000960 How I treat steroid-refractory acute graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/32202630/ PubMed]
 
*'''2020:''' Martin. [https://doi.org/10.1182/blood.2019000960 How I treat steroid-refractory acute graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/32202630/ PubMed]
 
*'''2019:''' Sarantopoulos et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6418480/ How I treat refractory chronic graft-versus-host disease]
 
*'''2019:''' Sarantopoulos et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6418480/ How I treat refractory chronic graft-versus-host disease]
 +
*'''2016:''' McDonald. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4807421/ How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver] [https://pubmed.ncbi.nlm.nih.gov/26729898/ PubMed]
 
*'''2014:''' Flowers & Martin. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304105/ How we treat chronic graft-versus-host disease]
 
*'''2014:''' Flowers & Martin. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304105/ How we treat chronic graft-versus-host disease]
 
*'''2012:''' Treister et al. [https://doi.org/10.1182/blood-2012-05-393389 How we treat oral chronic graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/22898605/ PubMed]
 
*'''2012:''' Treister et al. [https://doi.org/10.1182/blood-2012-05-393389 How we treat oral chronic graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/22898605/ PubMed]

Revision as of 00:06, 21 September 2023

The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.

In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.

Note: this page is currently under construction.

Malignant hematology

Myeloid neoplasms

Acute lymphoblastic leukemia (ALL)

Acute myeloid leukemia (AML)

Chronic myeloid leukemia (CML)

Essential thrombocythemia (ET)

Myelodysplastic syndrome (MDS)

Polycythemia vera (PV)

Lymphoid neoplasms

Adult T-cell leukemia-lymphoma (ATLL)

Burkitt lymphoma (BL)

Castleman disease

Chronic lymphocytic leukemia (CLL/SLL)

Cutaneous T-cell lymphoma (CTCL)

Hodgkin lymphoma

Diffuse large B-cell lymphoma (DLBCL)

Follicular lymphoma (FL)

Large granular lymphocytic leukemia (T-LGL)

NK- and T-cell lymphoma

Prolymphocytic leukemia (T-PLL)

Waldenström macroglobulinemia (WM)

Plasma cell dyscrasias

Light-chain (AL) amyloidosis

Multiple myeloma

Histiocytic disorders

Hemophagocytic lymphohistiocytosis (HLH)

Classical hematology

Hemostasis and thrombosis

Acquired thrombotic thrombocytopenic purpura (aTTP)

Antiphospholipid antibody syndrome (APS)

Arterial thromboembolism (ATE)

Hemophilia

Thrombotic microangiopathy (TMA)

Venous thromboembolism (VTE)

von Willebrand disease (vWD)

Cytopenias

Anemia

Autoimmune cytopenia

Immune thrombocytopenia (ITP)

Thrombocytopenia and platelet dysfunction

Hemoglobinopathies

Beta thalassemia

Sickle cell disease

Hemolytic disorders

Cold agglutinin disease (CAD)

Atypical hemolytic uremic syndrome (aHUS)

Paroxysmal nocturnal hemoglobinuria (PNH)

Warm autoimmune hemolytic anemia (WAIHA)

Special considerations

Age-based recommendations

Neonates

Children

Adolescents and young adults (AYA)

Older adults

Complications of treatment

Immune effector cells toxicity management

Infectious complications

Pregnancy

Transplatation

Allogeneic HSCT

Graft versus host disease (GVHD)